Daiichi's U.S. comPlexx

Buying Plexxikon jump starts Daiichi Sankyo's U.S. commercial presence in cancer

Although Roche has worldwide rights to Plexxikon Inc.'s PLX4032, the opportunity to jump start a U.S. commercial presence in cancer on the back of co-promotion rights is leading Daiichi Sankyo Co. Ltd. to acquire the biotech for $805 million up front.

Interim Phase III data for PLX4032 were reported in January, and Roche plans to submit marketing applications in the U.S. and Europe this year.

The deal also provides the Japanese pharma with two more clinical candidates and Plexxikon's scafforld-based discovery engine.

Glenn Gormley, Daiichi Sankyo's CSO and co-head of R&D, told BioCentury the company decided about a year ago

Read the full 977 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers